{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-036886","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.779314+00:00","generated_at":"2026-05-15T08:18:36.863951+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M","bullets":["Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).","Income from operations $0.2M, improved from operating loss of $1.9M; operating expenses fell 34% to $11.4M.","Cash and equivalents $2.1M at Dec 31, 2025, up from $1.4M at Dec 31, 2024.","Entered license/distribution deal with NeoImmuneTech for U.S. operations, expected Q2 2026.","Revenue drop driven by generic L-Glutamine competition in U.S., partially offset by MENA growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-036886","json":"https://secwatch.observer/filing/0001213900-26-036886.json","markdown":"https://secwatch.observer/filing/0001213900-26-036886.md","text":"https://secwatch.observer/filing/0001213900-26-036886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/0001213900-26-036886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/ea0283899-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:18:36.863951+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a54ac49af45a36f8b346e4f500b55c8f657a712","claim":"Emmaus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $12.5 million, net income net loss of $7.2 million, or $0.11 per share, EPS $0.11 per share.","evidence_excerpt":"Net revenues for the year ended December 31, 2025 were $12.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390026036886/0001213900-26-036886-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Revenue","value":"$12.5 million"},{"label":"Net income","value":"net loss of $7.2 million, or $0.11 per share"},{"label":"EPS","value":"$0.11 per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}